{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:08:38Z","timestamp":1785528518726,"version":"3.56.0"},"reference-count":16,"publisher":"Becaris Publishing Limited","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"abstract":"Plain language summary<\/jats:title>\n \n What is this article about?<\/jats:title>\n This article discusses the challenges of using non local real-world evidence (RWE) in health technology assessments (HTA) when local data are unavailable, insufficient, or inappropriate. HTA organizations often prefer data collected locally or regionally, but the lack of suitable data in many markets has increased interest in understanding data \u2018transportability\u2019 \u2013 whether data from one country or population can be used to predict outcomes in another. Established in 2024, the Flatiron Fostering Oncology RWE Use Cases and Methods (FORUM) research consortium is exploring when and how non-local RWE can be effectively applied, with initial work focused on lung cancer, breast cancer and multiple myeloma.<\/jats:p>\n <\/jats:sec>\n \n What does the evidence suggest so far?<\/jats:title>\n Initial studies suggest RWE from the US could predict outcomes in other countries with proper adjustment for population and treatment differences. Recent research in advanced non-small cell lung cancer demonstrated that adjusted US data provided comparable survival to real observed outcomes in Canada and the UK. This limited evidence base indicates that non-local RWE can help inform decision-making when local data is unavailable.<\/jats:p>\n <\/jats:sec>\n \n What studies are needed next?<\/jats:title>\n The FORUM consortium is expanding research to other cancer types and countries to better understand RWE transportability. Future studies will focus on comparing outcomes across diverse healthcare systems, identifying key variables for adjustment and developing guidelines for when and how non-local data can be used. These efforts aim to create a framework for the use of global RWE in oncology HTA decision-making.<\/jats:p>\n <\/jats:sec>","DOI":"10.57264\/cer-2025-0053","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T11:18:01Z","timestamp":1752146281000},"source":"Crossref","is-referenced-by-count":1,"title":["Crossing borders: the need for empirical evidence of real-world evidence transportability in oncology"],"prefix":"10.57264","author":[{"given":"Caitlin","family":"Clunie-O'Connor","sequence":"first","affiliation":[{"name":"Flatiron Health UK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Olof","family":"Thuresson","sequence":"additional","affiliation":[{"name":"Roche, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Masters","sequence":"additional","affiliation":[{"name":"Pfizer, New York City, NY 10001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliki","family":"Taylor","sequence":"additional","affiliation":[{"name":"Gilead, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Rosenlund","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Europe GmbH, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philani","family":"Mpofu","sequence":"additional","affiliation":[{"name":"Flatiron Health, New York, NY 10013, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4251-2912","authenticated-orcid":false,"given":"Blythe","family":"Adamson","sequence":"additional","affiliation":[{"name":"Flatiron Health, New York, NY 10013, USA"},{"name":"The Comparative Health Outcomes, Policy & Economics (CHOICE) Institute, University of Washington, Seattle, WA 98195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-023-01323-1"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0061"},{"key":"e_1_3_7_4_2","doi-asserted-by":"crossref","first-page":"837302","DOI":"10.3389\/fphar.2022.837302","article-title":"Real world data in health technology assessment of complex health technologies","volume":"13","author":"Hogervorst MA","year":"2022","unstructured":"Hogervorst MA, Pont\u00e9n J, Vreman RA, Mantel-Teeuwisse AK, Goettsch WG. Real world data in health technology assessment of complex health technologies. Front. Pharmacol. 13, 837302 (2022).","journal-title":"Front. Pharmacol."},{"issue":"10","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"e074559","DOI":"10.1136\/bmjopen-2023-074559","article-title":"Evaluation of US oncology electronic health record real-world data to reduce uncertainty in health technology appraisals: a retrospective cohort study","volume":"13","author":"Mpofu P","year":"2023","unstructured":"Mpofu P, Kent S, J\u00f3nsson P Evaluation of US oncology electronic health record real-world data to reduce uncertainty in health technology appraisals: a retrospective cohort study. BMJ Open 13(10), e074559 (2023).","journal-title":"BMJ Open"},{"key":"e_1_3_7_6_2","doi-asserted-by":"crossref","first-page":"1073678","DOI":"10.3389\/fmed.2022.1073678","article-title":"Transferability of real-world data across borders for regulatory and health technology assessment decision-making","volume":"9","author":"Jaksa A","year":"2022","unstructured":"Jaksa A, Arena PJ, Chan KKW, Ben-Joseph RH, J\u00f3nsson P, Campbell UB. Transferability of real-world data across borders for regulatory and health technology assessment decision-making. Front. Med. 9, 1073678 (2022).","journal-title":"Front. Med."},{"key":"e_1_3_7_7_2","unstructured":"Walker J. NICE updates real-world evidence framework to address new approaches in external validity and transportability of real-world data. (2024). Available at: https:\/\/becarispublishing.com\/digital-content\/blog-post\/nice-updates-real-world-evidence-framework-address-new-approaches-external-validity-and"},{"key":"e_1_3_7_8_2","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). Routine practice data in manufacturer dossiers: things are not yet running smoothly. (2022). Available at: https:\/\/www.iqwig.de\/en\/presse\/press-releases\/press-releases-detailpage_67103.html"},{"key":"e_1_3_7_9_2","unstructured":"Flatiron Health. Unlock critical evidence to accelerate access to cancer treatments worldwide. Available at: https:\/\/flatiron.com\/real-world-evidence\/value-access-hta"},{"key":"e_1_3_7_10_2","unstructured":"Real World Evidence Registry | Search. Available at: https:\/\/osf.io\/registries\/rwe\/discover"},{"issue":"12","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"S510","DOI":"10.1016\/j.jval.2023.09.2748","article-title":"RWD30 applying transportability methods to real-world data: a scoping review","volume":"26","author":"Wang H","year":"2023","unstructured":"Wang H, Tikhonovsky N, Gupta VA, Thompson A, Ramagopalan S, Duffield S. RWD30 applying transportability methods to real-world data: a scoping review. Value Health. 26(12), S510 (2023).","journal-title":"Value Health."},{"issue":"11","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"e2239874","DOI":"10.1001\/jamanetworkopen.2022.39874","article-title":"Transportability of overall survival estimates from US to Canadian patients with advanced non\u2013small cell lung cancer with implications for regulatory and health technology assessment","volume":"5","author":"Ramagopalan SV","year":"2022","unstructured":"Ramagopalan SV, Popat S, Gupta A Transportability of overall survival estimates from US to Canadian patients with advanced non\u2013small cell lung cancer with implications for regulatory and health technology assessment. JAMA Netw. Open 5(11), e2239874 (2022).","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"e_1_3_7_13_2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12885-021-08096-w","article-title":"Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom","volume":"21","author":"Lester J","year":"2021","unstructured":"Lester J, Escriu C, Khan S Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom. BMC Cancer 21(1), 515 (2021).","journal-title":"BMC Cancer"},{"issue":"12","key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"e085722","DOI":"10.1136\/bmjopen-2024-085722","article-title":"Evaluating transportability of overall survival estimates from US to UK populations receiving first-line treatment for advanced non-small cell lung cancer: a retrospective cohort study","volume":"14","author":"Kent S","year":"2024","unstructured":"Kent S, Mpofu P, Duffield S Evaluating transportability of overall survival estimates from US to UK populations receiving first-line treatment for advanced non-small cell lung cancer: a retrospective cohort study. BMJ Open 14(12), e085722 (2024).","journal-title":"BMJ Open"},{"issue":"12","key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"S426","DOI":"10.1016\/j.jval.2024.10.2184","article-title":"HTA359 Transportability of overall survival estimates from the US to England in metastatic breast cancer using nationally representative data sources","volume":"27","author":"Pittell H","year":"2024","unstructured":"Pittell H, Horne E, Mpofu P HTA359 Transportability of overall survival estimates from the US to England in metastatic breast cancer using nationally representative data sources. Value Health. 27(12), S426 (2024).","journal-title":"Value Health."},{"issue":"12","key":"e_1_3_7_16_2","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1016\/j.jval.2024.10.2044","article-title":"HTA219 Transporting real-world evidence: is it possible to transport OS estimates in HER2+ mBC from US to UK?","volume":"27","author":"Mpofu P","year":"2024","unstructured":"Mpofu P, Thuresson P, Sanglier T HTA219 Transporting real-world evidence: is it possible to transport OS estimates in HER2+ mBC from US to UK? Value Health. 27(12), S397 (2024).","journal-title":"Value Health."},{"issue":"12","key":"e_1_3_7_17_2","doi-asserted-by":"crossref","first-page":"S448","DOI":"10.1016\/j.jval.2024.10.2288","article-title":"MSR54 Anticipating the real-world impact of therapeutic innovations in France by transporting evidence from the United States (US): a case study in metastatic triple-negative breast cancer (mTNBC) based on the Flatiron Health Database","volume":"27","author":"Mbowen LS","year":"2024","unstructured":"Mbowen LS, Machuron V, Machuron G, Jegou R, Esnault C. MSR54 Anticipating the real-world impact of therapeutic innovations in France by transporting evidence from the United States (US): a case study in metastatic triple-negative breast cancer (mTNBC) based on the Flatiron Health Database. Value Health. 27(12), S448 (2024).","journal-title":"Value Health."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T11:18:11Z","timestamp":1752578291000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":16,"alternative-id":["10.57264\/cer-2025-0053"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0053","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"article-number":"e250053"}}